General Information


We are a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer, or NK, cell therapies to treat cancer. Our approach for cellular immunotherapy involves chimeric antigen receptors, or CARs, on the surface of an NK cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. The concept of a CAR builds upon and enhances the normal biology of T cells and NK cells, whereby naturally occurring receptors serve to activate these cells when a foreign pathogen or cancerous cell is detected. 

Employees: 70
Founded: 2015
Contact Information
Address 6000 Shoreline Court, Suite 102, South San Francisco, CA 94080, US
Phone Number 415-582-4923
Web Address http://www.nkartatx.com
View Prospectus: Nkarta
Financial Information
Market Cap $547.74mil
Revenues $02.3 mil (last 12 months)
Net Income $-26.7 mil (last 12 months)
IPO Profile
Symbol NKTX
Exchange NASDAQ
Shares (millions): 14.0
Price range $18.00 - $18.00
Est. $ Volume $252.0 mil
Manager / Joint Managers Cowen and Company/ Evercore/ Stifel/ Mizuho Securities
CO-Managers -
Expected To Trade: 7/10/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change